Satellos Bioscience Inc.

Recent News

• Satellos Bioscience Inc. Announces Licensing of Formulation Technology and Expanded Collaboration with NW PharmaTech Ltd.

  Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), is pleased to announce that its wholly owned subsidiary Amphotericin B Technologies Inc. ("AmpB Tech") and NW PharmaTech Ltd. ("NWPT") have today established a joint venture company, NW Micelle Therapeutics Inc. ("NWMT"), for the purpose of developing an oral formulation of cannabidiol for the treatment of insomnia and other indications in the mental health sphere ("Oral CBD"). NWPT will arrange for and provide...

  2022-10-06 5:19 PM EDT
• Satellos Bioscience Announces OTCQB Listing in the United States

  Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Corporation"), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that its common shares have commenced trading on the OTCQB Venture Market ("OTCQB") under the symbol "MSCLF". Shares in Satellos will continue to trade on the TSXV under the symbol MSCL."Listing on the...

  2022-10-06 8:18 AM EDT
• Satellos Bioscience Inc. Announces the Appointment of Philip D. Lambert, Ph.D, as Chief Technology Officer

  Toronto, Ontario--(Newsfile Corp. - September 28, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that its board of directors (the "Board") has appointed Philip Lambert, Ph.D., as Chief Technology Officer ("CTO") of the Company, effective September 27, 2022. "We are thrilled to welcome Dr. Lambert to our team as CTO, leading our translational research and development...

  2022-09-28 7:30 AM EDT
• Satellos Bioscience Inc. Announces Closing of Offering of Units

  Toronto, Ontario--(Newsfile Corp. - September 13, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce the closing of its previously announced public offering (the "Offering") of units of the Company ("Units"), whereby an aggregate of 8,750,000 Units were issued at a price of $0.40 per Unit, raising gross proceeds of $3,500,000. Each Unit consisted of one common...

  2022-09-13 9:05 AM EDT
• Satellos Bioscience Inc. Announces the Filing of Final Short Form Prospectus for Proposed Offering of Units

  Toronto, Ontario--(Newsfile Corp. - September 7, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has filed its final short form prospectus (the "Prospectus") with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with the Company's previously announced public offering of units ("Units") at a price of $0.40 per Unit...

  2022-09-07 4:01 PM EDT
• Satellos Bioscience Inc. Announces Pricing of Proposed Offering of Units

  Toronto, Ontario--(Newsfile Corp. - August 30, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has priced its previously announced proposed offering (the "Offering") of units of the Company ("Units"). Pursuant to the Offering, the Company will issue Units at a price of $0.40 per Unit for total minimum aggregate gross proceeds of $3,500,000 and maximum gross...

  2022-08-30 8:09 PM EDT
• Satellos Bioscience Inc. Announces the Filing of an Amended and Restated Preliminary Prospectus for Proposed Offering of Units

  Toronto, Ontario--(Newsfile Corp. - August 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has filed an amended and restated preliminary short form prospectus (the "Amended and Restated Preliminary Prospectus") with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario, amending and restating the Company's preliminary prospectus dated July 11, 2022. The...

  2022-08-29 8:53 PM EDT
• Satellos Bioscience Reports Q2 2022 Financials and Operating Results

  Toronto, Ontario--(Newsfile Corp. - August 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, filed its financial and operating results on 29 August 2022 for the quarter ended June 30, 2022. The Company's interim condensed consolidated financial statements for the quarter ended June 30, 2022, and the related management's discussion and analysis (MD&A) are available on SEDAR at www.sedar.com.About Satellos...

  2022-08-29 7:06 PM EDT
• Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Awarded Significant Grant from the Canadian Institutes of Health Research

  Toronto, Ontario--(Newsfile Corp. - July 25, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has been awarded a seven-figure, five-year grant from the Canadian Institutes of Health Research (CIHR). The grant entitled "Muscle Stem Cell Function in Duchenne Muscular Dystrophy" was awarded by the Genetics Research Panel....

  2022-07-25 7:00 AM EDT
• Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Published in Nature Communications

  Toronto, Ontario--(Newsfile Corp. - July 13, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has had new research published in the most recent edition of Nature Communications. The article, titled "GLI3 regulates muscle stem cell entry into GAlert and self-renewal", looks at the critical role that GLI3...

  2022-07-13 7:00 AM EDT